About this medicine

Atomoxetine can improve attention, hyperactivity and impulsivity. Benefit may develop over several weeks, and medicine is one part of broader ADHD support.

Regular review asks whether everyday functioning is improving at home, school, study or work, not merely whether the person feels more stimulated. Non-stimulant describes its pharmacological group; it does not mean monitoring or side-effect precautions are unnecessary.

What is this medicine used for?

Treatment is initiated by an ADHD specialist. Adult assessment includes evidence that symptoms were present in childhood. A medicine licence and a service’s treatment pathway are different questions.

ADHD assessment considers persistent symptoms and impairment across situations, rather than a single episode of poor concentration. The medicine's noradrenaline action does not create a depression indication, and it is not an immediate concentration aid to use only for a difficult task.

For children, this product’s licensed age range is separate from its place in the NICE treatment sequence. The ADHD article explains when this option may be considered after assessment, environmental changes and review of earlier treatment. Follow the exact formulation’s prescribing information and the agreed specialist monitoring plan.

Which warning signs need help?

New suicidal thinking, seizures, severe behavioural changes or signs of serotonin syndrome need urgent assessment. Stop atomoxetine and obtain immediate medical advice for jaundice or dark urine suggesting liver injury. Collapse or severe breathing difficulty is an emergency.

New chest pain or unexplained fainting needs prompt assessment. A prolonged painful erection also requires urgent care. The paediatric suicidal-thinking risk is explained through UK safety information, not relabelled as a UK FDA boxed warning.

How do I take it safely?

The checked adult SmPC starts at 40 mg daily for at least seven days before adjustment, with maintenance generally 80–100 mg daily and a 100 mg daily maximum. Children’s regimens depend on weight. These are licence summaries, not individual instructions.

The UK child schedule up to 70 kg starts around 0.5 mg/kg daily for at least seven days before adjustment, with a usual maintenance amount around 1.2 mg/kg daily. Weight and suitable capsule strengths matter. The American three-day initial interval must not be substituted for this UK schedule.

A separately checked Consilient Health liquid contains 4 mg/mL and is licensed for ADHD from six years, including adults. Its pack supplies a 10 mL oral syringe with 1 mL markings; use the prescribed volume and device rather than a kitchen spoon.

Do not mix the solution with food or water. The checked bottle has a 45-day period after first opening. A liquid can help with swallowing difficulties, but its concentration is not a daily dose.

What side effects should I know about?

Reduced appetite, nausea, headache, abdominal discomfort and sleep changes are reported. Adults can also experience sexual or urinary difficulties.

Ask about urinary difficulty and sexual side effects as well as nausea or appetite loss; people may not volunteer these symptoms. Changes in sleep, behaviour or mood should be assessed in relation to treatment timing and the wider clinical picture.

Who needs extra care with this medicine?

Contraindications include certain severe cardiovascular or cerebrovascular disorders, narrow-angle glaucoma, phaeochromocytoma and use around MAOI treatment. Liver impairment can require lower doses.

The checked oral solution contains sorbitol and should not be given to someone with hereditary fructose intolerance. Avoid eye contact; if solution enters an eye, rinse immediately with water and obtain medical advice.

Can it affect my other medicines?

Check antidepressants, medicines affecting heart rhythm or blood pressure, and cold remedies. Fluoxetine and paroxetine can increase atomoxetine exposure; serotonergic combinations can cause serotonin syndrome.

The product requires at least two weeks between atomoxetine and an MAOI in either direction. That interval is a safety boundary, not a switching plan. Medicines affecting cardiovascular function require particular attention even if they do not share atomoxetine's main target.

What check-ups will I need?

Check cardiovascular history, pulse and blood pressure before treatment, after dose changes and at least six-monthly. Growth and treatment benefit also need review. New cardiac symptoms require assessment.

MHRA advises careful pretreatment history and examination, with specialist cardiac review when findings suggest disease. Record pulse and pressure after adjustments and at least six-monthly, and assess cardiac symptoms promptly. A normal initial examination does not remove the need for follow-up.

What about pregnancy, breastfeeding and age?

Pregnancy and breastfeeding require specialist discussion because evidence is limited. The checked licence begins at age 6; adult licensing does not establish safety in every older person.

Limited evidence is not the same as proof of harm or proof of safety. Discuss treatment needs before conception where possible, and inform the maternity team if treatment continues. The absence of established use over 65 should remain explicit rather than extrapolating the adult regimen indefinitely.

What if I miss a dose or want to stop?

Do not double doses or exceed the prescribed daily total after a missed dose. Discuss stopping with the prescriber; ADHD symptoms can return even without a distinct withdrawal syndrome.

Absence of a typical withdrawal syndrome does not mean ongoing care is unnecessary. Treatment need should be reassessed rather than assumed lifelong; symptoms, functioning and tolerability help guide a planned change.

How does it work?

Atomoxetine reduces the return of noradrenaline, a chemical messenger, into nerve cells after it has been released. This allows more of the messenger to remain available between cells. Researchers do not yet fully understand how this action leads to improvement in attention-deficit/hyperactivity disorder (ADHD) symptoms.

How Brain Cells Communicate

Norepinephrine, also called noradrenaline, is one of the chemical messengers that nerve cells use to communicate. After release, it acts at receptors, proteins that receive the message and affect the receiving cell’s activity. Another protein, the norepinephrine transporter, returns the messenger into the sending cell. This return is called reuptake and helps regulate how long a message remains available.

What is known: The transporter helps remove norepinephrine from the space outside the cell.

What remains uncertain: A simplified account of this process cannot explain all the causes of someone’s attention difficulties.

Norepinephrine and NET

A transporter across a membrane, with the sending-cell interior above and released messenger outside below. The uptake direction is upward. Norepinephrine: The messenger is shown outside the sending cell. NET: This transporter returns norepinephrine from outside into the sending cell. Return into the cell: The arrow shows transport direction, without a measured rate.
  1. Norepinephrine

    The messenger is shown outside the sending cell.

  2. NET

    This transporter returns norepinephrine from outside into the sending cell.

  3. Return into the cell

    The arrow shows transport direction, without a measured rate.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

The NET transporter returns norepinephrine from outside the nerve cell into the cell. This is a separate transport system.

The transporter helps remove norepinephrine from the space outside the cell. Simplified illustration of the process; individual responses vary.
About this illustration

Norepinephrine released → Signal between cells → Transporter recycles. A simplified account of this process cannot explain all the causes of someone’s attention difficulties.

A simplified view of messenger release and return to a nerve cell.

Qualitative model · no scale, rate, dose or binding pose

How the Medication Changes Signaling

Atomoxetine selectively inhibits the norepinephrine transporter, meaning it reduces this transporter’s activity more strongly than that of some other messenger transporters. As a result, less norepinephrine is taken back into the nerve cell through that route. The medicine changes messenger handling rather than directly supplying norepinephrine. This is the best-established starting point for understanding its effects, while the full connection to treatment benefit remains uncertain.

What is known: Reducing transporter activity changes norepinephrine availability between cells.

What remains uncertain: Knowing this action does not predict the size or timing of a person’s improvement.

Atomoxetine and NET

A membrane transporter with uptake reduced; messenger remains outside below the membrane. The separate terracotta symbol denotes a medicine, not its molecular shape. Norepinephrine: The messenger is shown outside the sending cell. NET: This transporter returns norepinephrine from outside into the sending cell. Atomoxetine: uptake inhibited: The interrupted arrow names the action; the symbol is not a molecular shape or binding position.
  1. Norepinephrine

    The messenger is shown outside the sending cell.

  2. NET

    This transporter returns norepinephrine from outside into the sending cell.

  3. Atomoxetine: uptake inhibited

    The interrupted arrow names the action; the symbol is not a molecular shape or binding position.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Atomoxetine selectively inhibits the norepinephrine transporter. The full connection between this action and ADHD benefit remains incompletely understood.

Reducing transporter activity changes norepinephrine availability between cells. Simplified illustration of the process; individual responses vary.
About this illustration

Atomoxetine → Norepinephrine transporter → Reduced reuptake. Knowing this action does not predict the size or timing of a person’s improvement.

Transporter inhibition is shown qualitatively, without a molecular binding pose.

Qualitative model · no scale, rate, dose or binding pose

A Closer Look at the Molecular Level

Atomoxetine is supplied in a particular molecular arrangement called the R form; R describes how its atoms are arranged in space. The liver processes it mainly through CYP2D6, an enzyme, or protein that helps a chemical reaction occur. Inherited differences and other medicines can slow this processing, reducing clearance, which means the speed at which the body removes the medicine. This changes exposure, the amount present over time, without turning atomoxetine into a different medicine.

What is known: CYP2D6 activity influences how quickly atomoxetine is processed and removed.

What remains uncertain: An enzyme difference alone does not establish the best treatment or predict all unwanted effects.

How the process works

  1. R-atomoxetine
  2. CYP2D6 clearance varies
  3. Exposure / tolerability
CYP2D6 activity influences how quickly atomoxetine is processed and removed. Simplified illustration of the process; individual responses vary.
About this illustration

R-atomoxetine → CYP2D6 clearance varies → Exposure / tolerability. An enzyme difference alone does not establish the best treatment or predict all unwanted effects.

Metabolism affects exposure; this is not a personalized genetic or dosing prediction.

Qualitative model · no scale, rate, dose or binding pose

How does it affect my body?

Atomoxetine can increase pulse and blood pressure. This matters particularly for people whose cardiovascular condition could worsen with these changes.

The same messenger system acts beyond attention networks. Changes in pulse, pressure, appetite or urination can accompany benefit. The aim is a useful improvement with acceptable tolerability, not the largest physiological effect.

How does my body process it?

CYP2D6 is important in its metabolism. Genetic differences or medicines that inhibit this enzyme can increase exposure and change tolerability.

Poor CYP2D6 metabolisers have much higher exposure and may need a lower start or slower increase. The UK label halves initial and target doses in moderate liver impairment and uses a quarter in severe impairment. These are clinician-interpreted label adjustments, not instructions to split capsules.

How do treatment options differ?

NICE NG87 places atomoxetine among options after stimulant intolerance or insufficient response. This guidance should be read with the relevant national and local pathway.

Selective noradrenaline reuptake inhibition is sometimes abbreviated using the same letters as serotonin–noradrenaline antidepressants. The abbreviation is ambiguous; atomoxetine's ADHD licence, pharmacology and dosing must be checked by medicine name.

A closer look at the science

Its main molecular target is the presynaptic noradrenaline transporter. It does not directly inhibit serotonin or dopamine transporters in the same way.

Atomoxetine hydrochloride contains the R isomer of atomoxetine. The official drawing shows this stereochemistry and the hydrochloride component.

Chemical formula: C17H21NO · HCl

C, H, N, O and Cl represent carbon, hydrogen, nitrogen, oxygen and chlorine. The hydrochloride salt is identified separately; formula and handedness do not predict a clinical response.

Official atomoxetine hydrochloride structure with a dashed bond indicating the selected molecular stereochemistry.
Selected DailyMed label, section 11. The drawing identifies atomoxetine hydrochloride, not a protein-bound configuration.

How was this medicine developed?

A January 2012 MHRA safety update strengthened cardiovascular precautions. Its reference to Strattera explains the historical alias; it is not evidence of current branded stock.

The history of the Strattera name and later generic capsules is separate from evidence that a particular pack is currently supplied. This UK account retains that alias without importing the American brand's commercial status or newer American titration rules.

The Lincolnshire NHS formulary reports discontinuation of Strattera 4 mg/mL solution while noting a generic alternative. The current Consilient Health UK catalogue and its linked product information independently document a named generic solution. This separates an old brand's supply status from whether atomoxetine liquid has a UK product record; it is not a promise of local stock.

Sources and References

  1. Atomoxetine capsules: SmPC, sections 1–5

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  2. Atomoxetine 10–100 mg capsules: patient leaflet, sections 1–4

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  3. Atomoxetine: increases in blood pressure and heart rate (article dated January 2012)

    Scope: United Kingdom medicines safety.

  4. ADHD: diagnosis and management, NG87 recommendations 1.7.10, 1.7.15 and 1.7.17

    Scope: NICE guidance (England-based); applicability and implementation in other UK nations require the relevant national pathway.

  5. Atomoxetine 4 mg/mL oral solution: UK SmPC

    Scope: United Kingdom product information.

  6. Consilient Health UK product catalogue: Atomoxetine oral solution

    Scope: United Kingdom product catalogue.

  7. Lincolnshire Joint Formulary: CNS stimulants and ADHD medicines

    Scope: England — Lincolnshire local formulary; not a UK-wide commissioning rule.

  8. Atomoxetine / Strattera: current reference-product labeling
  9. ADHD: full recommendations PDF

    Scope: United Kingdom; NICE recommendations require attention to national implementation and local pathways.

  10. Atomoxetine / Strattera: FDA prescribing information, June 2026
  11. Serotonin syndrome: MedlinePlus Medical Encyclopedia
  12. Monitoring a person during and after antidepressant switching – NHS SPS - Specialist Pharmacy Service – The first stop for professional medicines advice

Shared scientific background. Some references are US product pharmacology or international chemical records; UK product details and prescribing information are verified separately.

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top